PharmaCorp Rx Inc.
PCRX.V
TSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -6.29% | 58.20% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -6.29% | 58.20% | |||
| Cost of Revenue | -6.68% | 64.10% | |||
| Gross Profit | -5.65% | 49.62% | |||
| SG&A Expenses | -23.42% | 44.14% | |||
| Depreciation & Amortization | 3.34% | 51.92% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.83% | 55.17% | |||
| Operating Income | 91.92% | -26.04% | |||
| Income Before Tax | 121.91% | -25.10% | |||
| Income Tax Expenses | -102.51% | 1,877.37% | |||
| Earnings from Continuing Operations | 114.44% | -112.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 37.79% | -63.16% | |||
| Net Income | 111.90% | -110.70% | |||
| EBIT | 91.92% | -26.04% | |||
| EBITDA | 175.35% | -11.77% | |||
| EPS Basic | 109.09% | -69.23% | |||
| Normalized Basic EPS | 111.11% | 0.00% | |||
| EPS Diluted | 109.09% | -69.23% | |||
| Normalized Diluted EPS | 111.11% | 0.00% | |||
| Average Basic Shares Outstanding | 17.09% | 26.75% | |||
| Average Diluted Shares Outstanding | 23.37% | 26.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||